替米沙坦对原发性高血压病合并2型糖尿病患者的心率变异性的影响  

Effects of telmisartan on heart rate variability in hypertensive patients with type 2 diabetes mellitus (DM)

作　　者：朱爱东[1] 何云[1] 王午喜 李茜[1] 吴莹[1] 

机构地区：[1]重庆市第五人民医院心内科,400062

出　　处：《实用心脑肺血管病杂志》2008年第1期5-7,共3页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：目的探讨原发性高血压病合并2型糖尿病患者的心率变异性(HRV)特点及替米沙坦对其的影响。方法50例原发性高血压病合并2型糖尿病患者,口服替米沙坦(80mg/d)8周前后HRV变化并与正常对照组(40例)比较。结果原发性高血压病合并2型糖尿病患者的HRV治疗前明显低于正常人,予替米沙坦8周干预治疗后HRV值明显上升。低频功率与高频功率比值(LF/HF)显著降低(P<0.01)。结论原发性高血压病合并2型糖尿病患者自主神经活动明显受损,其迷走神经张力降低,交感神经张力相对增高,发生心源性猝死的危险性明显增加。替米沙坦能有效地提高心脏迷走神经张力,降低交感神经张力,有可能减少心律失常性死亡。Objective To investigate the effect of telmisartan on heart rate variability （HRV） in patients with essential hypertension （EH） and type 2 diabetes mellitus （DM）. Methods 50 patients with EH and DM took telmisartan （80mg/d） orally for 8 weeks. The change of HRV were analyzed and compared with that of 40 healthy controls. Results The HRV of patients with EH and DM was lower than that of normal controls. After telmisartan treatment, the SDNN, RMSSD, PNN 50 and HF increased but LF/HF decreased markedly （P〈0.01）. Conclusion Telmisartan can increase cardiac vagal activity and decrease sympathetic activity in patients with EH and DM, which suggests that telmisartan may reduce the arrhythmic mortality.

关 键 词：原发性高血压 2型糖尿病 替米沙坦 心率变异性 

分 类 号：R544.1[医药卫生—心血管疾病] R587.1[医药卫生—内科学]